EIP
LJPC

Ellis Investment Partners’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Ellis Investment Partners’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,800
Closed -$8K – 847
2022
Q2 		$8K Hold
2,800
– – ﹤0.01% 626
2022
Q1 		$11K Hold
2,800
– – ﹤0.01% 615
2021
Q4 		$13K Hold
2,800
– – ﹤0.01% 596
2021
Q3 		$11K Hold
2,800
– – ﹤0.01% 595
2021
Q2 		$11K Sell
2,800
-300
-10% -$1.28K ﹤0.01% 600
2021
Q1 		$13K Hold
3,100
– – ﹤0.01% 552
2020
Q4 		$12K Hold
3,100
– – ﹤0.01% 545
2020
Q3 		$12K Hold
3,100
– – ﹤0.01% 544
2020
Q2 		$14K Hold
3,100
– – 0.01% 502
2020
Q1 		$14K Buy
+3,100
New +$19.6K 0.01% 446

Ellis Investment Partners's LJPC Position: Q3 2022 in Review

Ellis Investment Partners sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2022, closing a stake of 2,800 shares — an estimated $8K sold.

Ellis Investment Partners first reported a position in LJPC in Q1 2020 and held it in 10 quarters. The position peaked at $14K in Q2 2020. 0 funds tracked by Wall St. Rank hold LJPC as of Q3 2022.

  • Ellis Investment Partners reported no remaining La Jolla Pharmaceutical Company position as of Q3 2022 after selling out during the quarter.
  • Ellis Investment Partners sold 2,800 La Jolla Pharmaceutical Company shares in Q3 2022, an estimated $8K.
  • Ellis Investment Partners first reported a position in La Jolla Pharmaceutical Company in Q1 2020 and held it in 10 quarters.
  • Ellis Investment Partners's La Jolla Pharmaceutical Company position peaked at $14K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2022.

Based on Ellis Investment Partners's 13F filing for Q3 2022, filed 14 Nov 2022.